Sidley Represents ADARx Pharmaceuticals in Its US$200 Million Series C Financing
August 9, 2023
Related Professionals
Offices
Stay Up To Date
Sidley represented ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing next-generation RNA therapeutics, in its successful close of an oversubscribed US$200 million Series C financing led by Bain Capital and TCGX. The proceeds from the Series C financing will be used to further advance ADARx’s clinical programs, including drug candidates for the treatment of multiple complement-mediated diseases and hereditary angioedema, and to support advancement of a pipeline of innovative mRNA silencing or editing candidates.
The Sidley team was led by James Lu (Emerging Companies and Venture Capital) and Feifei Bian (M&A), and included Jake Funk and Derek W. Kang (M&A).
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.
You have successfully set your edition to United States. Would you like to make this selection your default edition?
*Selecting a default edition will set a cookie.
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.